Michael R. McKellar, BA

home / authors / michael-r-mckellar-ba

Articles

April 23rd 2014

The Economics of Resistant Pathogens and Antibiotic Innovation

Michael R. McKellar, BA Michael E. Chernew, PhD A. Mark Fendrick, MD

March 18th 2014

The Economics of Resistant Pathogens and Antibiotic Innovation

Michael R. McKellar, BA Michael E. Chernew, PhD A. Mark Fendrick, MD

This commentary discusses why antibiotics and the treatment of infectious diseases present a special case for pharmaceutical development, pricing, and appropriate utilization.

Latest Updated Articles

Transgender | Image credit: Olga Tsikarishvili - stock.adobe.com

Published: August 18th 2025 | Updated: August 25th 2025

Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults

Semaglutide | Image credit: Peter Hansen - stock.adobe.com

Published: August 19th 2025 | Updated: August 22nd 2025

Semaglutide Not Associated With Increased Risk of Eye Disorders

On-body delivery system | Image credit: Enable Injections

Published: June 6th 2025 | Updated: August 18th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

drug shortages in the US | Image credit: OntheRun Photo - stock.adobe.com

Published: June 27th 2025 | Updated: July 1st 2025

Report Reveals Mounting Burdens of Drug Shortages on US Health System

Published: February 20th 2025 | Updated: February 21st 2025

Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP

Hands holding pack of cigarettes | Image credit: Nopphon – stock.adobe.com

Published: January 16th 2025 | Updated: January 29th 2025

FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions